Project description
Innovative metabolism-based diagnostic platform for cancer patient follow-up
Cancer patients require regular follow-ups to detect recurrences early and optimise treatment strategies. The current surveillance approaches often result in late detection. Swedish Elypta has developed the first metabolism-based liquid biopsy to detect early-stage recurrences. The detection platform has demonstrated exceptional sensitivity with low cost, enabling frequent patient follow-ups. The technology has been tested in small clinical trials. The objectives of the EU-funded AURORAX project are to conduct a broad clinical validation trial, obtain regulatory clearance in the EU and the United States, and introduce the product for research as well as to the renal cell carcinoma diagnostics market in the EU.
Fields of science
Programme(s)
Funding Scheme
SME-2 - SME instrument phase 2Coordinator
ELYPTA AB
Net EU contribution
€ 2 342 671,00
Address
Regeringsgatan 65, 3tr
111 56 Stockholm
Sweden
111 56 Stockholm
Sweden
See on map
Region
Östra Sverige Stockholm Stockholms län
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Other funding
€ 2 342 671,00